API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The in vitro data, in GBM cells and patient-derived glioma-initiating cells, show anti-tumour activity of the Company's lead asset SFX-01. In both models, SFX-01 reduced tumour growth substantially and demonstrated statistically significant improved survival.
Lead Product(s): Sulforaphane
Therapeutic Area: Oncology Product Name: SFX-01
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2021
Details:
JadiCells, as well as QuadraMune®, a commercially available nutraceutical developed by the Company have been shown to reduce lung scarring in other experiments.
Lead Product(s): Pterostilbene,Green Tea Extract,Sulforaphane
Therapeutic Area: Infections and Infectious Diseases Product Name: QuadraMune
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2021
Details:
The net proceeds of the Fundraising are intended to be used to complete the formulation and scale up manufacturing of SFX-01 and other R&D nd general corporate purposes.
Lead Product(s): Sulforaphane,Alpha-Cyclodextrin
Therapeutic Area: Oncology Product Name: SFX-01
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $15.3 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 02, 2021
Details:
The data generated for SFX-01 in standard pre-clinical models and orthotopic models (where glioma cells are implanted in brain tissue representing a more disease-relevant model) show tumour shrinkage and significantly extended survival times.
Lead Product(s): Sulforaphane
Therapeutic Area: Oncology Product Name: SFX-01
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 21, 2021
Details:
A total of 56 patients had been recruited and randomised to the STAR trial ("SFX-01 treatment for Acute Respiratory Infections").SFX-01 upregulates the Nrf2 pathway which is part of the natural human defence against inflammatory and oxidative stress.
Lead Product(s): Sulforaphane,Alpha-Cyclodextrin
Therapeutic Area: Infections and Infectious Diseases Product Name: SFX-01
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: University of Dundee
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2021
Details:
Using a standard test for natural killer cell activity, the K562 lysis assay, 12 healthy volunteers taking one week of placebo had an average activity of 2.3 (±0.6), whereas those taking one week of QuadraMune™ had an average activity of 5.2 (±1.2), almost double.
Lead Product(s): Pterostilbene,Green Tea Extract,Sulforaphane
Therapeutic Area: Infections and Infectious Diseases Product Name: QuadraMune
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 24, 2020
Details:
This Phase II/III trial will investigate whether the Company's lead asset, SFX-01, can reduce the severity, or prevent the onset of, acute respiratory distress syndrome in patients with community-acquired pneumonia who have been or are being tested for suspected COVID-19.
Lead Product(s): Sulforaphane
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: SFX-01
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2020
Details:
QuadraMune™ is a nutraceutical developed by the Company which is currently in a clinical trial for prevention of COVID-19[1]. Minocycline is an antibiotic that is approved by the FDA.
Lead Product(s): Pterostilbene,Green Tea Extract,Sulforaphane
Therapeutic Area: Psychiatry/Psychology Product Name: QuadraMune
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 28, 2020
Details:
Pterostilbene is one of four ingredients which comprise QuadraMune™, a nutraceutical being developed by the Company which is currently in a clinical trial for prevention of COVID-19.
Lead Product(s): Pterostilbene,Green Tea Extract,Sulforaphane
Therapeutic Area: Neurology Product Name: QuadraMune
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2020
Details:
In a series of animal studies using the triple-negative breast cancer 4T1 mouse model, the Company showed that administration of QuadraMune™ reduced lung metastasis on its own and increased efficacy of a “cancer vaccine.
Lead Product(s): Pterostilbene,Green Tea Extract,Sulforaphane
Therapeutic Area: Oncology Product Name: QuadraMune
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2020
Details:
Administration of daily doses of QuadraMune™ in healthy volunteers results in statistically significant increases in immune response activity within 5 days.
Lead Product(s): Pterostilbene,Sulforaphane,Green Tea Extract
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 01, 2020